Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 412

1.

Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy.

Guimbellot JS, Ryan KJ, Anderson JD, Liu Z, Kersh L, Esther CR, Rowe SM, Acosta EP.

J Cyst Fibros. 2020 Feb 7. pii: S1569-1993(20)30035-7. doi: 10.1016/j.jcf.2020.01.011. [Epub ahead of print]

PMID:
32044246
2.

Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial.

Devanand DP, Andrews H, Kreisl WC, Razlighi Q, Gershon A, Stern Y, Mintz A, Wisniewski T, Acosta E, Pollina J, Katsikoumbas M, Bell KL, Pelton GH, Deliyannides D, Prasad KM, Huey ED.

BMJ Open. 2020 Feb 6;10(2):e032112. doi: 10.1136/bmjopen-2019-032112.

3.

Age-specific incidence of influenza A responds to change in virus subtype dominance.

Gagnon A, Acosta E, Miller MS.

Clin Infect Dis. 2020 Jan 27. pii: ciaa075. doi: 10.1093/cid/ciaa075. [Epub ahead of print]

PMID:
31985006
4.

Raltegravir (RAL) in neonates: Dosing, pharmacokinetics (PK), and safety in HIV-1 exposed neonates at risk of infection (IMPAACT P1110).

Clarke DF, Acosta EP, Cababasay M, Wang J, Chain A, Teppler H, Popson S, Graham B, Smith B, Hazra R, Calabrese K, Bryson Y, Spector SA, Lommerse J, Mirochnick M; IMPAACT P1110 Protocol Team.

J Acquir Immune Defic Syndr. 2020 Jan 6. doi: 10.1097/QAI.0000000000002294. [Epub ahead of print]

PMID:
31913995
5.

Predicting the effect of additives on wormlike micelle and liquid crystal formation and rheology with phase inversion phenomena.

Choi F, Chen R, Acosta EJ.

J Colloid Interface Sci. 2020 Mar 22;564:216-229. doi: 10.1016/j.jcis.2019.12.105. Epub 2019 Dec 26.

PMID:
31911226
6.

The value of hydrologic information for watershed management programs: The case of Camboriú, Brazil.

Hamel P, Bremer LL, Ponette-González AG, Acosta E, Fisher JRB, Steele B, Cavassani AT, Klemz C, Blainski E, Brauman KA.

Sci Total Environ. 2020 Feb 25;705:135871. doi: 10.1016/j.scitotenv.2019.135871. Epub 2019 Dec 2.

7.

Formulating and Retaining the Structure of Polymerized Surfactant Phases Using a Microemulsion Curvature Framework.

Choi F, Nirmal G, Pizzardi M, Acosta EJ.

Langmuir. 2019 Dec 24;35(51):16821-16834. doi: 10.1021/acs.langmuir.9b02822. Epub 2019 Dec 9.

PMID:
31755720
8.

Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis.

Meyers T, Samson P, Acosta EP, Moye J, Townley E, Bradford S, Marillo L, Denson K, Hovind L, Sise T, Teppler H, Mathiba SR, Masenya M, Hesseling A, Cotton MF, Krogstad P; IMPAACT P1101 Team.

AIDS. 2019 Nov 15;33(14):2197-2203. doi: 10.1097/QAD.0000000000002369.

PMID:
31689263
9.

Correction to: Determinants of Influenza Mortality Trends: Age-Period-Cohort Analysis of Influenza Mortality in the United States, 1959-2016.

Acosta E, Hallman SA, Dillon LY, Ouellette N, Bourbeau R, Herring DA, Inwood K, Earn DJD, Madrenas J, Miller MS, Gagnon A.

Demography. 2019 Oct 28. doi: 10.1007/s13524-019-00824-z. [Epub ahead of print]

PMID:
31659681
10.

Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110.

Clarke DF, Mirochnick M, Acosta EP, Capparelli E, Chain A, Teppler H, Smith B, Lommerse J; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1110 Study Team.

J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):392-398. doi: 10.1097/QAI.0000000000002149.

PMID:
31658182
11.

Characterizing the Oil-like and Surfactant-like Behavior of Polar Oils.

Ghayour A, Acosta E.

Langmuir. 2019 Nov 26;35(47):15038-15050. doi: 10.1021/acs.langmuir.9b02732. Epub 2019 Nov 15.

PMID:
31633933
12.

Interfacial Tension of the Water-Diluted Bitumen Interface at High Bitumen Concentrations Measured Using a Microfluidic Technique.

Goel S, Joshi N, Uddin MS, Ng S, Acosta E, Ramachandran A.

Langmuir. 2019 Dec 3;35(48):15710-15722. doi: 10.1021/acs.langmuir.9b02253. Epub 2019 Nov 15.

PMID:
31631660
13.

Osteopenia and Osteoporosis in Patients with Bronchiectasis: Association with Respiratory Parameters, Body Composition, Muscle Strength and Bone Remodeling Biomarkers.

Contreras-Bolívar V, Olveira G, Porras N, Acosta E, Rubio-Martín E, Tapia-Guerrero MJ, Abuin-Fernández J, Olveira C.

Sci Rep. 2019 Oct 10;9(1):14496. doi: 10.1038/s41598-019-51069-0.

14.

The Leptin induced Hic-5 expression and actin puncta formation by the FAK/Src-dependent pathway in MCF10A mammary epithelial cells

Isaías-Tizapa R, Acosta E, Tacuba-Saavedra A, Mendoza-Catalán M, Navarro-Tito N.

Biomedica. 2019 Sep 1;39(3):547-560. doi: 10.7705/biomedica.4313. English, Spanish.

15.

Determinants of Influenza Mortality Trends: Age-Period-Cohort Analysis of Influenza Mortality in the United States, 1959-2016.

Acosta E, Hallman SA, Dillon LY, Ouellette N, Bourbeau R, Herring DA, Inwood K, Earn DJD, Madrenas J, Miller MS, Gagnon A.

Demography. 2019 Oct;56(5):1723-1746. doi: 10.1007/s13524-019-00809-y. Erratum in: Demography. 2019 Oct 28;:.

16.

Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing.

Lommerse J, Clarke D, Kerbusch T, Merdjan H, Witjes H, Teppler H, Mirochnick M, Acosta EP, Wenning L, Nachman S, Chain A.

CPT Pharmacometrics Syst Pharmacol. 2019 Sep;8(9):643-653. doi: 10.1002/psp4.12443. Epub 2019 Jul 10.

17.

Reciprocal Effects of Fibroblast Growth Factor Receptor Signaling on Dengue Virus Replication and Virion Production.

Cortese M, Kumar A, Matula P, Kaderali L, Scaturro P, Erfle H, Acosta EG, Buehler S, Ruggieri A, Chatel-Chaix L, Rohr K, Bartenschlager R.

Cell Rep. 2019 May 28;27(9):2579-2592.e6. doi: 10.1016/j.celrep.2019.04.105.

18.

Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210.

Johnson VA, Cramer YS, Rosenkranz SL, Becker S, Klingman KL, Kallungal B, Coakley E, Acosta EP, Calandra G, Saag MS; NIH/NIAID AIDS Clinical Trials Group A5210 Protocol Team.

AIDS Res Hum Retroviruses. 2019 Aug;35(8):691-697. doi: 10.1089/AID.2018.0256. Epub 2019 Jun 18.

PMID:
31099252
19.

Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.

Viani RM, Ruel T, Alvero C, Fenton T, Acosta EP, Hazra R, Townley E, Palumbo P, Buchanan AM, Vavro C, Singh R, Graham B, Anthony P, George K, Wiznia A; P1093 Study Team .

J Pediatric Infect Dis Soc. 2019 Apr 5. pii: piy139. doi: 10.1093/jpids/piy139. [Epub ahead of print]

PMID:
30951600
20.

Anti-vimentin antibodies in transplant and disease.

Divanyan T, Acosta E, Patel D, Constantino D, Lopez-Soler RI.

Hum Immunol. 2019 Aug;80(8):602-607. doi: 10.1016/j.humimm.2019.03.017. Epub 2019 Mar 26. Review.

PMID:
30926354
21.

Solid-Liquid-Liquid Wettability of Surfactant-Oil-Water Systems and Its Prediction around the Phase Inversion Point.

Stammitti-Scarpone A, Acosta EJ.

Langmuir. 2019 Mar 26;35(12):4305-4318. doi: 10.1021/acs.langmuir.8b03907. Epub 2019 Mar 12.

PMID:
30821467
22.

Returns on investment in watershed conservation: Application of a best practices analytical framework to the Rio Camboriú Water Producer program, Santa Catarina, Brazil.

Kroeger T, Klemz C, Boucher T, Fisher JRB, Acosta E, Cavassani AT, Dennedy-Frank PJ, Garbossa L, Blainski E, Santos RC, Giberti S, Petry P, Shemie D, Dacol K.

Sci Total Environ. 2019 Mar 20;657:1368-1381. doi: 10.1016/j.scitotenv.2018.12.116. Epub 2018 Dec 11.

PMID:
30677903
23.

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.

Nyaku AN, Zheng L, Gulick RM, Olefsky M, Berzins B, Wallis CL, Godfrey C, Sax PE, Acosta EP, Haas DW, Smith KY, Sha BE, Van Dam CN, Taiwo BO; ACTG A5353 Study Team .

J Antimicrob Chemother. 2019 May 1;74(5):1376-1380. doi: 10.1093/jac/dky564.

24.

Study of arterial stiffness in patients with an acute coronary event and chronic obstructive pulmonary disease confirmed by spirometry.

Almagro P, Acosta E, Navarro A, Murillo MF, Valdivielso S, de la Sierra A.

Rev Clin Esp. 2019 Jun - Jul;219(5):251-255. doi: 10.1016/j.rce.2018.08.007. Epub 2019 Jan 16. English, Spanish.

PMID:
30660321
25.

Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Acosta EP, Mager DE, Morse GD; AIDS Clinical Trials Group Study A5202 Team.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01638-18. doi: 10.1128/AAC.01638-18. Print 2019 Apr.

26.

Transdermal Delivery of Enfuvirtide in a Porcine Model Using a Low-Frequency, Low-Power Ultrasound Transducer Patch.

Snook KA, Van Ess R 2nd, Werner JR, Clement RS, Ocon-Grove OM, Dodds JW, Ryan KJ, Acosta EP, Zurlo JJ, Mulvihill ML.

Ultrasound Med Biol. 2019 Feb;45(2):513-525. doi: 10.1016/j.ultrasmedbio.2018.10.003. Epub 2018 Dec 21.

27.

Solid-liquid-liquid wettability and its prediction with surface free energy models.

Stammitti-Scarpone A, Acosta EJ.

Adv Colloid Interface Sci. 2019 Feb;264:28-46. doi: 10.1016/j.cis.2018.10.003. Epub 2018 Oct 25. Review.

PMID:
30396508
28.

Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.

Reshef R, Ganetsky A, Acosta EP, Blauser R, Crisalli L, McGraw J, Frey NV, Hexner EO, Hoxie JA, Loren AW, Luger SM, Mangan J, Stadtmauer EA, Mick R, Vonderheide RH, Porter DL.

Biol Blood Marrow Transplant. 2019 Mar;25(3):515-521. doi: 10.1016/j.bbmt.2018.09.034. Epub 2018 Oct 10.

PMID:
30315941
29.

Oil-induced formation of branched wormlike micelles in an alcohol propoxysulfate extended surfactant system.

Choi F, Acosta EJ.

Soft Matter. 2018 Nov 7;14(41):8378-8389. doi: 10.1039/c8sm01673a. Epub 2018 Oct 12.

PMID:
30310914
30.

Reporting and evaluating influenza virus surveillance data: An argument for incidence by single year of age.

Gagnon A, Acosta E, Miller MS.

Vaccine. 2018 Oct 8;36(42):6249-6252. doi: 10.1016/j.vaccine.2018.08.077. Epub 2018 Sep 12. No abstract available.

PMID:
30219370
31.

Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV.

Momper JD, Best BM, Wang J, Capparelli EV, Stek A, Barr E, Badell ML, Acosta EP, Purswani M, Smith E, Chakhtoura N, Park K, Burchett S, Shapiro DE, Mirochnick M; IMPAACT P1026s Protocol Team.

AIDS. 2018 Nov 13;32(17):2507-2516. doi: 10.1097/QAD.0000000000001992.

32.

Cyclic flexural fatigue resistance of NiTi Controlled Memory and Blue Technology instruments after torsional preloading.

Modesto TC, Acosta ECP, Resende PD, Pereira ÉSJ, Peixoto IFDC, Buono VTL, Viana ACD.

J Appl Oral Sci. 2018;26:e20180144. doi: 10.1590/1678-7757-2018-0144. Epub 2018 Aug 20.

33.

Determination of the thermal boundary conductance of gold nanoparticles in aqueous solution using a method based on nanobubble generation.

Gonzalez MG, Acosta EO, Santiago GD.

Appl Opt. 2018 Jul 20;57(21):6229-6232. doi: 10.1364/AO.57.006229.

PMID:
30118005
34.

The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.

Namazi G, Fajnzylber JM, Aga E, Bosch RJ, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, Smith DM, Kuritzkes DR, Gulick RM, Mellors JW, Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks SG, Chun TW, Collier AC, Routy JP, Hecht FM, Walker BD, Li JZ.

J Infect Dis. 2018 Nov 5;218(12):1954-1963. doi: 10.1093/infdis/jiy479.

35.

HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers.

Sharaf R, Lee GQ, Sun X, Etemad B, Aboukhater LM, Hu Z, Brumme ZL, Aga E, Bosch RJ, Wen Y, Namazi G, Gao C, Acosta EP, Gandhi RT, Jacobson JM, Skiest D, Margolis DM, Mitsuyasu R, Volberding P, Connick E, Kuritzkes DR, Lederman MM, Yu XG, Lichterfeld M, Li JZ.

J Clin Invest. 2018 Aug 31;128(9):4074-4085. doi: 10.1172/JCI120549. Epub 2018 Aug 20.

36.

HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy.

Lahiri CD, Brown NL, Ryan KJ, Acosta EP, Sheth AN, Mehta CC, Ingersoll J, Ofotokun I.

AIDS. 2018 Sep 24;32(15):2151-2159. doi: 10.1097/QAD.0000000000001945.

37.

Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.

Haas DW, Bradford Y, Verma A, Verma SS, Eron JJ, Gulick RM, Riddler SA, Sax PE, Daar ES, Morse GD, Acosta EP, Ritchie MD.

Pharmacogenet Genomics. 2018 Jul;28(7):179-187. doi: 10.1097/FPC.0000000000000341.

38.

Evolutionary adaptation of an RNA bacteriophage to the simultaneous increase in the within-host and extracellular temperatures.

Lázaro E, Arribas M, Cabanillas L, Román I, Acosta E.

Sci Rep. 2018 May 24;8(1):8080. doi: 10.1038/s41598-018-26443-z.

39.

Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation.

Bull ME, Mitchell C, Soria J, Styrchak S, Williams-Wietzikoski C, Legard J, McKernan-Mullin J, Kraft K, Onchiri F, Stern J, Holte S, Ryan KJ, Acosta EP, La Rosa A, Coombs RW, Ticona E, Frenkel LM.

AIDS. 2018 Jul 17;32(11):1389-1401. doi: 10.1097/QAD.0000000000001824.

40.

Diagnosing catheter-associated urinary tract infection: Still a matter of concern.

Jordano Q, Molina M, Acosta E, Xercavins M, de la Sierra A.

Eur J Intern Med. 2018 Jun;52:e30-e31. doi: 10.1016/j.ejim.2018.03.001. Epub 2018 Mar 8. No abstract available.

PMID:
29526652
41.

Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer.

Guimbellot JS, Acosta EP, Rowe SM.

Pediatr Pulmonol. 2018 May;53(5):E6-E8. doi: 10.1002/ppul.23971. Epub 2018 Feb 28.

42.

Rewiring cellular networks by members of the Flaviviridae family.

Neufeldt CJ, Cortese M, Acosta EG, Bartenschlager R.

Nat Rev Microbiol. 2018 Feb 12;16(3):125-142. doi: 10.1038/nrmicro.2017.170. Review.

PMID:
29430005
43.

Central blood pressure variability is increased in hypertensive patients with target organ damage.

de la Sierra A, Pareja J, Yun S, Acosta E, Aiello F, Oliveras A, Vázquez S, Armario P, Blanch P, Sierra C, Calero F, Fernández-Llama P.

J Clin Hypertens (Greenwich). 2018 Feb;20(2):266-272. doi: 10.1111/jch.13172. Epub 2018 Jan 25.

44.

Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.

Mulligan N, Best BM, Wang J, Capparelli EV, Stek A, Barr E, Buschur SL, Acosta EP, Smith E, Chakhtoura N, Burchett S, Mirochnick M; IMPAACT P1026s Protocol Team.

AIDS. 2018 Mar 27;32(6):729-737. doi: 10.1097/QAD.0000000000001755.

45.

Pandemic Paradox: Early Life H2N2 Pandemic Influenza Infection Enhanced Susceptibility to Death during the 2009 H1N1 Pandemic.

Gagnon A, Acosta E, Hallman S, Bourbeau R, Dillon LY, Ouellette N, Earn DJD, Herring DA, Inwood K, Madrenas J, Miller MS.

mBio. 2018 Jan 16;9(1). pii: e02091-17. doi: 10.1128/mBio.02091-17.

46.

Pupil size stability of the cubic phase mask solution for presbyopia.

Almaguer C, Acosta E, Arines J.

J Biomed Opt. 2018 Jan;23(1):1-8. doi: 10.1117/1.JBO.23.1.015002.

47.

Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.

Taiwo BO, Marconi VC, Berzins B, Moser CB, Nyaku AN, Fichtenbaum CJ, Benson CA, Wilkin T, Koletar SL, Colasanti J, Acosta EP, Li JZ, Sax PE.

Clin Infect Dis. 2018 May 17;66(11):1794-1797. doi: 10.1093/cid/cix1131.

48.

Risk Factors for Unfavorable Outcomes in Surgically Treated Brainstem Cavernous Malformations.

Nathal E, Patiño-Rodriguez HM, Arauz A, Imam SS, Acosta E, Evins AI, Longo GM.

World Neurosurg. 2018 Mar;111:e478-e484. doi: 10.1016/j.wneu.2017.12.105. Epub 2017 Dec 26.

PMID:
29288109
49.

ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.

Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, Godfrey C, Sax PE, Acosta E, Haas D, Smith KY, Sha B, Van Dam C, Gulick RM.

Clin Infect Dis. 2018 May 17;66(11):1689-1697. doi: 10.1093/cid/cix1083.

50.

Vector polynomials for direct analysis of circular wavefront slope data: erratum.

Mahajan VN, Acosta E.

J Opt Soc Am A Opt Image Sci Vis. 2017 Dec 1;34(12):2250. doi: 10.1364/JOSAA.34.002250.

PMID:
29240101

Supplemental Content

Loading ...
Support Center